4 Topic Commentaries

CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis

• 

  John D. Isaacs, MD, PhD

  Rheumatology

  •

  Newcastle University

  Nonetheless, treatment is still considered to be disease-suppressive and lifelong in most cases.

  Source
• 

  Georg Schett, MD

  Rheumatology/Immunology

  •

  Friedrich-Alexander-Universität Erlangen–Nürnberg (FAU) and Universitätsklinikum Erlangen

  Pathogenic B cell activation underlies many autoimmune diseases (AIDs), and their depletion is an attractive therapeutic approach.

  Source
• 

  Sarah Kayser, MD

  Hematology/Oncology

  •

  Charité – Universitätsmedizin Berlin

  CAR T-cell therapy represents an evolution of this concept, offering targeted and tissue-penetrant immunoablation with the potential for reduced systemic toxicity.

  Source
• 

  David Simon, MD

  Rheumatology

  •

  Charité – Universitätsmedizin Berlin

  CD19 CAR T cells showed acceptable short-term tolerability in patients with treatment-refractory RA, justifying further evaluation.

  Source